Cargando…
Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant
BACKGROUND: There is a clear need for vaccines and therapeutics for potential biological weapons of mass destruction and emerging diseases. Anthrax, caused by the bacterium Bacillus anthracis, has been used as both a biological warfare agent and bioterrorist weapon previously. Although antibiotic th...
Autores principales: | Kelly, Cassandra D, O'Loughlin, Chris, Gelder, Frank B, Peterson, Johnny W, Sower, Laurie E, Cirino, Nick M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2104530/ https://www.ncbi.nlm.nih.gov/pubmed/17953756 http://dx.doi.org/10.1186/1476-8518-5-11 |
Ejemplares similares
-
Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide
Publicado: (1986) -
Central pyrogenic activity of muramyl dipeptide
Publicado: (1980) -
Muramyl dipeptide: Not just another brick in the wall
por: Viswanathan, VK
Publicado: (2014) -
The Role of the Bacterial Muramyl Dipeptide in the Regulation of GLP-1 and Glycemia
por: Williams, Laura, et al.
Publicado: (2020) -
Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide
por: Coulombe, François, et al.
Publicado: (2009)